Literature DB >> 25619924

Hypoxia-induced relaxation of porcine retinal arterioles in vitro depends on inducible NO synthase and EP4 receptor stimulation in the perivascular retina.

Pernille Oversø Hansen1, Sidse Kringelholt1, Ulf Simonsen2, Toke Bek1.   

Abstract

PURPOSE: Hypoxia-induced relaxation of porcine retinal arterioles has been shown to be reduced during inhibition of prostaglandin synthesis and nitric oxide synthase (NOS). The purpose of this study was to identity the specific prostaglandin receptor(s) and source(s) of NO mediating this effect.
METHODS: Porcine retinal arterioles with preserved perivascular retinal tissue were mounted in a myograph and were exposed to hypoxia in the presence of one of the following: the general NO synthase inhibitor L-NAME, the selective iNOS inhibitor 1400W, the selective nNOS inhibitor 7-nitroindazole, the general cyclooxygenase (COX) inhibitor ibuprofen or an antagonist to the FP- (AL 8810), DP- (BWA868C), EP1 - (SC-19220), EP2 - (PF-044189) or EP4 receptors (GW627368X). The experiments were repeated after removal of the perivascular retinal tissue.
RESULTS: Hypoxia induced relaxation of retinal arterioles with preserved perivascular retinal tissue. This relaxation was significantly reduced in the presence of L-NAME, 1400W, ibuprofen and the EP4 receptor antagonist GW627368X. The simultaneous addition of L-NAME or 1400W in combination with ibuprofen, but not GW627368X, reduced hypoxia-induced vasorelaxation additively as compared to the effect of the compounds individually.
CONCLUSION: Hypoxia-induced vasorelaxation of porcine retinal arterioles is mediated by inducible NOS and stimulation of EP4 receptors acting through separate pathways, but mechanisms unrelated to the studied prostaglandin receptors and NOS products are also involved.
© 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  in vitro experiments; nitric oxide; porcine retinal arterioles; prostaglandins; retinal hypoxia

Mesh:

Substances:

Year:  2015        PMID: 25619924     DOI: 10.1111/aos.12669

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  7 in total

1.  The diameter response of retinal arterioles in diabetic maculopathy is reduced during hypoxia and is unaffected by the inhibition of cyclo-oxygenase and nitric oxide synthesis.

Authors:  Line Petersen; Toke Bek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-07       Impact factor: 3.117

2.  Post-hypoxic constriction of retinal arterioles is impaired during nitric oxide and cyclo-oxygenase inhibition and in diabetic patients without retinopathy.

Authors:  Line Petersen; Toke Bek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

Review 3.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 4.  Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors.

Authors:  Najam A Sharif
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

5.  Lack of effect of nitroglycerin on the diameter response of larger retinal arterioles in normal persons during hypoxia.

Authors:  Musa Yasin Kaya; Line Petersen; Toke Bek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-30       Impact factor: 3.117

6.  Acute and Chronic Hyperglycemia Elicit JIP1/JNK-Mediated Endothelial Vasodilator Dysfunction of Retinal Arterioles.

Authors:  Travis W Hein; Wenjuan Xu; Xin Xu; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

7.  Regulatory mechanism of melatonin on the retinal ganglion cell photoreaction in mice.

Authors:  Jianqiao Li; Jiongwan Hong; Fang Zhou; Shibo Tang; Xinyi Wu
Journal:  Exp Ther Med       Date:  2017-06-26       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.